SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing significant volatility and community debate after pulling its compounded GLP-1 drug amid a patent infringement lawsuit from Novo Nordisk and increased regulatory scrutiny. Investors are sharply divided between calls for a short squeeze and a rebound from oversold levels, and predictions of further downside due to ongoing legal and business model challenges.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending after announcing a $5.8 billion all-stock acquisition of Valaris, a move generating buzz as a strategic consolidation to create an offshore drilling leader, aiming to boost cash flow and benefit from an emerging industry upcycle, despite some investor caution regarding potential share dilution.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is currently trending after its stock dramatically dropped following news of an SEC review into its accounting practices, reduced guidance, and the departure of its CFO and General Counsel. The community is sharply divided, with some calling it an extreme "overreaction" and a unique "buy-the-dip" opportunity, while others express severe concerns about potential financial improprieties, urging investors to "stay away" until more clarity emerges.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending after its Q4 earnings report, which, despite a revenue miss, beat EPS estimates and outlined an optimistic outlook for 2026, including the expiration of a value-destructive slab contract and ongoing POSCO partnership discussions. While some in the community view the stock's subsequent dip as a buying opportunity driven by these future catalysts, others remain deeply skeptical about its performance and management.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending due to a significant stock drop following its Q4 earnings report, which, despite showing profitability and prudent risk management, included a revenue miss and cautious guidance. The community is actively debating if the sell-off is an overreaction, viewing it as a potential buying opportunity given the company's strong fundamentals and AI-powered model, while others remain concerned about the broader fintech sector's volatility.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending following a puzzling stock dip, which occurred despite strong earnings and raised guidance, prompting community discussion about whether an overreaction to its Super Bowl commercial or broader market sentiment is creating a 'buying opportunity'.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com's stock is plummeting after issuing weaker-than-expected guidance, sparking widespread investor fears about AI disrupting the traditional software business model. The community is sharply divided, with many fearing obsolescence for SaaS platforms while others view the significant drop as an oversold opportunity.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as Morgan Stanley initiates coverage with an Overweight rating and a $37 price target, validating its strategic pivot to AI/HPC data centers amidst increasing hyperscaler capital expenditure. The community is actively discussing potential for a significant short squeeze and further contracts with major tech partners.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending with high volatility as its February 8th PDUFA date for RGX-121 approaches, amidst a recent clinical hold on the therapy and a related program due to a patient's brain tumor, leaving the community sharply divided on whether a significant drop from a Complete Response Letter or a delay is more likely.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending as the community discusses its strategic acquisition of StereoLabs, which creates a unified lidar and camera platform for Physical AI applications. This move is largely seen as strengthening Ouster's market leadership and accelerating its path to profitability through StereoLabs' EBITDA-positive business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Glioblastoma multiforme (GBM) is an aggressive, fast-growing brain and spinal cord tumor that generally has a poor prognosis with a low median survival rate.</li><li>Patients treated with Temferon in the study had a median overall survival remains at 17 months, consistent with prior findings.</li><li>A patient in the study also reached three years of survival following Temferon administration, the company said.</li></ul>Shares of Genenta Science (GNTA) soared 10% in the pre-market session on Monday after the company announced long-term survival trends from the study of its cell therapy in the treatment of some newly diagnosed glioblastoma multiforme (GBM) patients.Glioblastoma multiforme (GBM) is an aggressive, fast-growing brain and spinal cord tumor that generally has a poor prognosis with a low median survival rate. Genenta is studying Temferon, an experimental cell therapy, in the patient population.<h2 class="st-heading-2">What Does The Study Show?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193229/0/en/Genenta-Reports-Long-Term-Survival-Trends-and-Immune-Findings-in-Brain-Tumor-GBM-Trial.html">said</a> that 25 patients have been treated with Temferon as of November 21, and 44% of patients have reached 18-month survival. This marks an increase from April, when the company had announced that 38% of patients had reached 18-month survival.Median overall survival remains at 17 months, consistent with prior findings, while the two-year survival rate continues to be 29%, the company said, while adding that median overall survival on standards of care is typically 13-15 months with a two-year survival rate of about 14%.A patient in the study also reached three years of survival following Temferon administration, the company said. Overall, the study also provided early immune observations on Temferon’s behavior within the tumor microenvironment, it added. The observations must now be confirmed in larger, controlled studies.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GNTA jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:584/55;" src="data:image/png;base64,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" width="584" height="55"><figcaption>GNTA’s Sentiment Meter and Message Volume as of 6:15 a.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/GNTA">GNTA stock</a> is down by 61% this year and by about 65% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/deere-q4-earnings-seen-under-pressure-amid-weak-farmer-sentiment/cL5bdq0REfH">Deere Q4 Earnings Seen Under Pressure Amid Weak Farmer Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the Genenta Science logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Genenta Stock Rises Pre-Market After Cell Therapy Improves Survival In Certain Tumor Patients

The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.

Equity

The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.


<ul class="summary-bullets"><li>Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE.</li><li>The partnership aims to advance an off-the-shelf LVV Plasmid DNA platform to improve gene therapy production.</li><li>Genenta Science is a clinical-stage biotech company focused on developing immuno-oncology therapies.</li></ul>Genenta Science (GNTA) stock is set to hit an all-time high on Friday after the company announced that it has joined forces with biotech manufacturing organization ANEMOCYTE to develop tools for gene and cell therapy.&nbsp;At&nbsp;the time of writing&nbsp;<a href="https://stocktwits.com/symbol/GNTA">Genenta Science stock</a> traded over 300% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;The collaboration centers on developing an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform to boost the production of high-quality genetic materials used in advanced therapies.<h2 class="st-heading-2">Expanded Partnership</h2>The new strategic agreement strengthens an already productive relationship between the two firms, previously focused on Plasmid DNA manufacturing.&nbsp;The companies intend to combine Genenta’s experience with LVV Plasmid DNA technology, originally derived from the research of co-founder Professor Luigi Naldini, with ANEMOCYTE’s production capabilities to deliver dependable materials for research and clinical applications.What Is Genenta Science Known For?&nbsp;Genenta Science is a clinical-stage biotech company focused on developing immuno-oncology therapies that harness hematopoietic stem cells to fight tumor cancers. Its lead candidate, Temferon, is engineered to deliver immune-activating payloads directly within the tumor microenvironment through modified bone marrow-derived cells, aiming for a precise and lasting anti-cancer effect.<blockquote>“By making our clinically validated LVV Plasmid DNA technology platform available to ANEMOCYTE and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry.”-Pierluigi Paracchi, CEO, Genenta Science.</blockquote>Genenta Science's stock has lost over 25% in 2025 and over 39% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alphabet-apple-meta-lead-private-funding-for-trump-s-white-house-ballroom/cLGJQyRR3s4">Alphabet, Apple, Meta Lead Private Funding For Trump’s ‘Big, Beautiful’ $250M White House Ballroom Project, Donor List Reveals</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A piece of a plasmid model is stained at Biontech's Goerzhausen I site.

GNTA Stock Skyrockets 300% Pre-Market Toward Record Highs: What’s Driving The Super Rally?

Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE.

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

Genenta Science SpA - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

GNTA
Genenta Science SpA - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest GNTA News

GNTAGenenta Science SpA - ADR